The biopharmaceutical company Boehringer Ingelheim has signed a new collaboration agreement with the Germans Trias i Pujol Research Institute (IGTP) to launch a new research project focused on evaluating the potential benefit of a new molecule in the cardiovascular-renal-metabolic axis.
The alliance between both institutions is part of a strategic collaboration initiated in 2020 between Boehringer Ingelheim and the Geramns Trias Hospital Heart Institute (iCor) linked to the IGTP with the aim of improving knowledge about cardiovascular, renal and metabolic pathologies (CRM), also exploring the interconnection that is established between these diseases, with the aim of advancing the understanding of the pathologies and enabling the development of new innovative strategies for their prevention and treatment. Over the years, the teams have worked on four projects that have studied the effect of empagliflozin on heart failure and myocardial infarction, in addition to exploring new possible therapeutic targets. The last of these studies, recently published in the Journal of the American Heart Association, has evaluated how empagliflozin can contribute to improving the functioning of the heart in situations of myocardial infarction.
“Innovation is part of our DNA, and this alliance is a clear example of our commitment to continue promoting science as an engine of transformation. Working on projects from preclinical research with the IGTP reinforces our conviction that, through collaboration between institutions, we can generate a real impact in improving people’s lives,” says Martín Plotquin, Director of Medicine and R&D at Boehringer Ingelheim Spain. “This new alliance is part of our global strategy to promote innovation through alliances with reference centers such as the IGTP,” adds Plotquin.
For his part, Dr. Antoni Bayés-Genís, director of iCor, points out that “this collaboration reinforces our commitment to translational research in the cardiovascular, renal and metabolic fields. The joint work with Boehringer Ingelheim has allowed us to advance in the knowledge of key pathophysiological mechanisms and explore new therapeutic strategies with a clear potential for clinical impact. This new preclinical line opens the door to continuing to generate scientific evidence that can benefit patients in the near future.”
This new agreement is part of Boehringer Ingelheim’s strategy to continue promoting innovation as a driver of transformation in the healthcare system. In fact, in 2024 the company increased its investment in R&D by 53%, reaching 105 million euros. Of this total, 20.4 million euros were invested in clinical research in Spain. Boehringer Ingelheim has 107 basic, preclinical and clinical research projects underway with more than 70 reference centers in Spain.
